Skip to main content

Dexcom Value Stock - Dividend - Research Selection

Dexcom

ISIN: US2521311074 , WKN: A0D9T1

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


S&P 500 Posts Eighth Consecutive Weekly Gain Led by Health Care, Utilities

2026-05-22
The Standard & Poor's 500 index rose 0.9% this week, its eighth consecutive week of gains, amid upbe

QuantumCore Announces Changes to Board of Directors

2026-05-22
Toronto, Ontario--(Newsfile Corp. - May 22, 2026) - QuantumCore Ltd. (CSE: QNCR) (FSE: K1Y) ("QuantumCore" or the "Company") is pleased to announce that David Marantz has been appointed to the Company's board of directors (the "Appointment"). David Marantz is a technology and healthcare executive with over 15 years of experience scaling high-growth companies, raising capital, and leading strategic transformations across healthcare, benefits, and SaaS. Mr. Marantz currently serves as the chief...

DexCom Flex Launch Targets Wider Type 2 Market With Valuation Upside

2026-05-22
DexCom (NasdaqGS:DXCM) has launched Dexcom Flex, a new continuous glucose monitoring system for Type 2 diabetes patients who are not on intensive insulin therapy. The product is initially rolling out in Germany, expanding access to CGM technology for a broader group of patients. Dexcom Flex targets a segment of the Type 2 population that has historically had limited exposure to CGM devices. DexCom is best known for its CGM systems used by people with diabetes to track glucose levels in real...

Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years

2026-05-22

Harnessing medtech market alliances, ŌURA sets IPO plans in motion

2026-05-22
The Oura Ring creator’s plans to go public follow a $900m fundraise in October 2025 that put the company at an $11bn valuation.

Analysts Upgrade DexCom (DXCM) to “Outperform,” Driving Share Recovery

2026-05-22
Alpha Wealth Funds, LLC, an investment management company, released its Q1 2025 letter for the “Insiders Fund”. A copy of the letter can be downloaded here. The fund lost 7.14% in the quarter, tied to a 6.75% fall in March due to the War in Iran. This compares to the S&P 500’s -4.33% return for […]

DexCom Might Finally Be Cheap Enough

2026-05-21
DexCom's improved fundamentals and a 15% lower stock price present a more attractive entry. Learn why DXCM stock is a Buy.

Live Longer and Better. Does Medicine’s New Obsession Really Work?

2026-05-21
The longevity industry is booming with high-tech tests, drugs, and medical devices. What to know for your health—and personal finances.

The DexCom Stock Turnaround Is Showing Real Signs of Life

2026-05-20
DexCom (DXCM) shares have put together an encouraging short-term bounce as the company maps out a multi-year growth algorithm. The stock currently carries a 8% “Sell” rating, but that’s up from the prior day’s 96% “Sell” rating and 100% “Sell” last week. A positive trend on that indicator. DXCM is...

Stay informed with the top movers within the S&P500 index on Tuesday.

2026-05-19
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.